Auricular Vagus Nerve Stimulation for Pain Relief in Long COVID

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial investigates the use of auricular transcutaneous vagus nerve stimulation (tVNS) to alleviate pain in patients suffering from long-term symptoms following COVID-19 infection. It focuses on individuals experiencing various types of pain, including nociceptive, neuropathic, and nociplastic pain, which may persist after the acute phase of the illness. The study is a prospective, non-randomized pilot feasibility trial lasting 8 weeks, utilizing a TENS device to stimulate the vagus nerve through the ear. The aim is to evaluate the effectiveness of this neuromodulation technique in reducing pain levels in affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Subjects aged 18 to 80 with prolonged post-Covid-19 pain defined by 3 criteria according to the Haute Autorité de Santé :

* Symptomatic initial episode of Covid-19 is confirmed by at least one criterion among: PCR SARS-CoV-2 +, antigenic test SARS-CoV-2 +, Serology SARS-CoV-2 +, prolonged anosmia / ageusia of sudden onset , chest scanner
* Presence of at least one of the initial symptoms, beyond 4 weeks following the onset of the acute phase of the disease
* Initial and prolonged symptoms not explained by another diagnosis with no known link to Covid-19

  * With intact and uninjured skin at the level of the cymba concha of the left ear
  * Signature of informed consent
  * Pain of intensity\> or equal to 40 mm / 100mmm on the Visual Analogue Scale (VAS) over the last 7 days before inclusion, analgesic treatment stable for at least 2 weeks
  * Must be able to comply with protocol requirements
  * Beneficiary of a social security scheme or entitled

Exclusion Criteria:

* Having a hearing aid device with a left cochlear implant
* Having a major hearing loss
* Having an unsuitable ear canal
* Use of other electrically active medical devices (TENS for chronic pain, pacemaker)
* Taking treatment with strong opioids, corticosteroids or nonsteroidal anti-inflammatory drugs systemically (oral, subcutaneous, intravenous, intramuscular, transdermal).
* With cognitive disorders that do not allow answering questionnaires and /or setting up the device
* Known history of cardiac arrhythmias, atrioventricular block\> 1st degree, conduction disorders
* Symptomatic orthostatic hypotension or history of recurrent vagal syncope
* History of vagotomy
* severe asthma
* Pregnant, breastfeeding or having a desire to become pregnant

Where it's running

• Service Centre d'Evaluation et de Traitement de la Douleur
  Paris, France Recruiting

Study contacts

• Principal investigator: Stéphanie Mauboussin Carlos — Assistance Publique - Hôpitaux de Paris
• Study coordinator: Stéphanie Mauboussin Carlos
• Email: stephanie.mauboussincarlos@aphp.fr
• Phone: +33 1 49 28 23 06

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.